Results 11 to 20 of about 125 (92)

Efficacy and safety of netakimab in patients with psoriatic arthritis: results of the phase III PATERA clinical study

Научно-практическая ревматология, 2020
Netakimab (NTK) is a humanized anti-interleukin-17А (IL-17A) monoclonal antibody approved for the treatment of psoriatic arthritis, ankylosing spondylitis, moderate to severe psoriasis.
T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaydukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Eremeeva, M. A. Morozova   +8 more
doaj   +3 more sources

Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial

Dermatology and Therapy, 2021
Background. Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate to severe plaque psoriasis in a phase 2 clinical study.
Luis Puig, Maria Morozova, Arina Zinkina-Orikhan   +2 more
exaly   +3 more sources

Current treatment for spondyloarthritis: focus on netakimab. A review

Терапевтический архив
Spondyloarthritis (SpA) is a group of rheumatic diseases that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA) and a number of other diseases. SpA lead to a significant social problem, since it is a common pathology that debuts mainly at a
Dmitry E. Karateev, Elena L. Luchikhina
doaj   +3 more sources

Pleiotropic effects of netakimab in patients with psoriatic arthritis, spondylitis and comorbid metabolic syndrome or a new opportunity for weight control? Case report [PDF]

Терапевтический архив
The article presents the results of studying the efficacy of netakimab (Efleira) in the complex treatment of patients with psoriasis, psoriatic arthritis, spondylitis and concomitant metabolic syndrome.
Alida K. Karibova, Seypula Sh. Akhmedkhanov, Magomed T. Kudaev, Ekaterina A. Azizova   +3 more
doaj   +2 more sources

Pharmacoeconomic analysis of netakimab in the treatment of ankylosing spondylitis: perspective of Russian healthcare system

Фармакоэкономика
Objective: to evaluate clinical and economic effectiveness of netakimab therapy for ankylosing spondylitis (AS) in comparison with other biological disease-modifying antirheumatic drugs (bDMARDs) currently employed in clinical practice in the Russian ...
A. V. Rudakova, I. Z. Gaydukova
doaj   +2 more sources

Long-term efficacy and impact of netakimab on the cardiometabolic profile in patients with psoriasis

Meditsinskiy Sovet
Introduction . Psoriasis is associated with chronic systemic inflammation and an increased cardiometabolic risk. The role of IL-17A inhibition in modifying these processes in long-term real-world clinical practice requires further investigation. Aim .
Olga Zhukova
exaly   +2 more sources

Real-World Retention Rate, Effectiveness, and Safety of Netakimab in the Treatment of Patients with Ankylosing Spondylitis: Two-Year Results of the Real Word Evidence LIBRA Study

Doklady Biochemistry and Biophysics
Under real-world clinical practice together with indices for assessing disease activity and the effectiveness of therapy, drug retention provides critical information on efficacy, safety, compliance and convenience of use.The aim – to obtain data on the ...
Shandor Erdes, I F Umnova, I B Vinogradova   +2 more
exaly   +3 more sources

Extracorporeal photochemotherapy in secondary clinical nonresponse to netakimab in patients with psoriasis: case reports

Russian Journal of Skin and Venereal Diseases
Psoriasis is one of the most prevalent and socially important skin diseases. For a long time, the main treatment approaches included a combination of topical therapies, physiotherapeutic methods, and systemic agents targeting keratinocyte proliferation.
Anton Molochkov
exaly   +2 more sources

Pharmacoeconomic analysis of the netakimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Federation

Medical Technologies Assessment and Choice (Медицинские технологии Оценка и выбор)
Objective. To evaluate the economic feasibility of expanding the use of netakimab for the treatment of adult patients with moderate to severe psoriasis vulgaris compared to other biologics and small molecules used in the health care settings of the Russian Federation. Material and methods.
A.V. Pavlysh, A.L. Bakulev
exaly   +2 more sources

Dynamics of laboratory markers of endothelial dysfunction in patients with psoriatic arthritis under the influence of the interleukin-17A inhibitor netakimab

Современная ревматология
Objective: a comparative evaluation of the effect of the interleukin-17A inhibitor (iIL) netakimab (NTK) and methotrexate (MTX) on laboratory markers of endothelial dysfunction in patients with psoriatic arthritis (PsA) in comparison with the dynamics of
A. V. Petrov, O. A. Pritulo, A. A. Petrov   +2 more
doaj   +2 more sources